Literature DB >> 28867422

Serum albumin levels and depression in people living with Human Immunodeficiency Virus infection: a cross-sectional study.

Kalpana Poudel-Tandukar1, Cynthia S Jacelon2, Elizabeth R Bertone-Johnson3, Paula H Palmer4, Krishna C Poudel5.   

Abstract

BACKGROUND: Lower serum albumin levels and depression are common among HIV-infected persons. High serum albumin levels may provide protection against depression through its defensive role in inflammation and infection. We tested the hypothesis of an independent relationship between serum albumin levels and depressive symptoms in a cohort of HIV-infected persons.
METHODS: A cross-sectional survey was conducted among 310 HIV-infected persons (176 men and 134 women) aged 20-60years residing in the Kathmandu Valley, Nepal. The bromocresol green method was used to measure serum albumin levels and the Beck Depression Inventory method was used to measure depressive symptoms, with a cut off score of 20 or higher indicating likely depression. The relationship between serum albumin levels and depressive symptoms was assessed using both multiple linear regression analysis and multiple logistic regression analysis, with adjustment for sociodemographic, cardiovascular, life-style, and HIV-related clinical and treatment confounding factors.
RESULTS: Serum albumin levels were inversely associated with depressive symptoms scores (beta for 1 unit change in serum albumin levels: β=-3.91; p=0.001) for the total participant sample. This inverse association was significant in both men (β=-3.93; p=0.009) and women (β=-4.47; p=0.03). A significantly decreased risk of depression was observed among participants with the highest serum albumin levels, with odds ratio and 95% CI for those with >5.0g/dL versus <4.0g/dL of 0.22 (0.06-0.80) (p=0.01).
CONCLUSION: Serum albumin levels were inversely associated with depressive symptoms scores in HIV-infected persons.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Albumin; Depression; Developing country; HIV/AIDS

Mesh:

Substances:

Year:  2017        PMID: 28867422     DOI: 10.1016/j.jpsychores.2017.08.005

Source DB:  PubMed          Journal:  J Psychosom Res        ISSN: 0022-3999            Impact factor:   3.006


  5 in total

1.  ROS-Targeted Depression Therapy via BSA-Incubated Ceria Nanoclusters.

Authors:  Shengyang Fu; Huili Chen; Weitao Yang; Xiaohuan Xia; Shu Zhao; Xiaonan Xu; Pu Ai; Qingyuan Cai; Xiangyu Li; Yi Wang; Jie Zhu; Bingbo Zhang; Jialin C Zheng
Journal:  Nano Lett       Date:  2022-05-18       Impact factor: 12.262

2.  New lung cancer treatments (immunotherapy and targeted therapies) and their associations with depression and other psychological side effects as compared to chemotherapy.

Authors:  Daniel C McFarland
Journal:  Gen Hosp Psychiatry       Date:  2019-04-18       Impact factor: 3.238

3.  Inflammation in Relation to Intensity and Duration of Cigarette Smoking Among People Living with HIV.

Authors:  Krishna C Poudel; Kalpana Poudel-Tandukar; Elizabeth R Bertone-Johnson; Penelope Pekow; Damon J Vidrine
Journal:  AIDS Behav       Date:  2020-09-28

4.  Depression and Inflammation in Patients With Lung Cancer: A Comparative Analysis of Acute Phase Reactant Inflammatory Markers.

Authors:  Daniel C McFarland; William Breitbart; Andrew H Miller; Christian Nelson
Journal:  Psychosomatics       Date:  2020-04-02       Impact factor: 2.386

5.  The association between serum albumin and depression in chronic liver disease may differ by liver histology.

Authors:  Junyan Cao; Weihong Qiu; Yong Yu; Na Li; Huixiang Wu; Zhaocong Chen
Journal:  BMC Psychiatry       Date:  2022-01-04       Impact factor: 3.630

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.